Holen Sie sich die Stockscreener-App
435.65
0.64%
-3.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$438.71
Offen:
$437.79
24-Stunden-Volumen:
318.37K
Relative Volume:
0.22
Marktkapitalisierung:
$110.64B
Einnahmen:
$12.07B
Nettoeinkommen (Verlust:
$3.95B
KGV:
28.41
EPS:
15.3349
Netto-Cashflow:
$3.19B
1W Leistung:
-1.64%
1M Leistung:
-4.55%
6M Leistung:
+8.19%
1J Leistung:
-8.16%
1-Tages-Spanne:
$435.26
$440.90
1-Wochen-Bereich:
$435.26
$453.98
52-Wochen-Spanne:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
435.76 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.73 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.26 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.72 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.87 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Biotech layoff pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Best Biotech Stocks To Follow NowApril 5th - MarketBeat
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals EVP Sells $439,288 in Stock - National Today
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock - MarketBeat
Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan - Stock Titan
Vertex Pharmaceuticals Inc (VX1.MU) Stock Forum & Discussion - Yahoo! Finance Canada
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup - ChartMill
Aberdeen Group Reduces Stake in Vertex Pharmaceuticals - National Today
Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex (NASDAQ: VRTX) posts $12B 2025 revenue and sets 2026 proxy votes - Stock Titan
Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX) - Seeking Alpha
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - AOL.com
The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It - inc.com
F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA - MarketBeat
Vertex Advances FDA Filing for IgA Nephropathy Therapy - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Submits Biologics Licensing Application for Accelerated FDA Approval - GuruFocus
Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales - Stock Titan
FDA Expands Vertex (VRTX) Drugs' Usage for Cystic Fibrosis - GuruFocus
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor) - marketscreener.com
Vertex Pharmaceuticals IncFDA expands indication for trikafta in cf patients ages 2 and older - marketscreener.com
Vertex wins FDA label expansion for cystic fibrosis drugs - Seeking Alpha
, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - businesswire.com
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex (VRTX) CMO sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated Completes Submission of Biologics Licensing Application for Povetacicept to the U.S. Food and Drug Administration - marketscreener.com
[8-K] VERTEX PHARMACEUTICALS INC / MA Reports Material Event - Stock Titan
Promising Biotech Stocks To Watch NowMarch 31st - MarketBeat
Fierce Biotech Layoff Tracker 2026: Takeda plots 634 US job cuts - Fierce Biotech
Boston Common Asset Management LLC Sells 20,952 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - simplywall.st
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex’s VX-407 Contraceptive Interaction Study Reaches Completion: What Investors Should Watch - TipRanks
BMO reiterates Vertex stock Outperform on cystic fibrosis strength By Investing.com - Investing.com UK
Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat
Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 - Insider Monkey
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard (VRTX) parent reports 0 shares; subsidiaries to report holdings separately - Stock Titan
Vertex Pharmaceuticals Tumbles Over 3.4% – What’s Behind the Sudden Drop? - Bitget
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):